Apelin has been described as endogenous ligand for human APJ. Its pyroglutaminated C-terminal peptide [Pyr1]-Apelin-13 ( [pGlu]-Apelin-13 ) was more potent than Apelin-36 in competitive inhibition assays. PeptaNova | Peptide Institute Inc. offers both Apelin peptides in highest quality for research purposes.